Loading…
Pfizer Inc. is projected to rise to $28.18 by 2027, a +17% move from its current price of $24.17. PFE is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $23.90 | $24.17 | $24.46 | +0.02% |
| Jul 14 | $23.79 | $24.18 | $24.58 | +0.04% |
| Jul 15 | $23.70 | $24.18 | $24.67 | +0.05% |
| Jul 16 | $23.63 | $24.19 | $24.75 | +0.07% |
| Jul 17 | $23.57 | $24.19 | $24.82 | +0.09% |
| Jul 18 | $23.52 | $24.20 | $24.89 | +0.11% |
| Jul 19 | $23.47 | $24.20 | $24.95 | +0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $23.47 | $24.20 | $24.95 | +0.12% |
| Week 2 | $23.21 | $24.23 | $25.30 | +0.25% |
| Week 3 | $23.01 | $24.26 | $25.58 | +0.37% |
| Week 4 | $22.85 | $24.29 | $25.82 | +0.50% |
| Week 5 | $22.71 | $24.32 | $26.04 | +0.63% |
| Week 6 | $22.59 | $24.35 | $26.24 | +0.75% |
| Week 7 | $22.49 | $24.38 | $26.44 | +0.88% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Pfizer Inc. is a healthcare company that discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite.
Its portfolio includes internal medicine products under the Eliquis brand for cardiovascular metabolic diseases; migraine products under Nurtec ODT/Vydura and Zavzpret; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology medicines such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for cancers under many brands including Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna; biosimilars under Inflectra and related lines; and sterile injectables such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin.
Pfizer was founded in 1849 and is headquartered in New York, New York.
It has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models.
Pfizer Inc. (PFE) is a healthcare company currently trading at $25.08, with a market cap of $142.94B and ranked 97.
The stock’s near-term technical posture is NEUTRAL, with RSI14 at 40, a SMA50 of 26.20 and a SMA200 of 25.88. Price could tread around a near-term area defined by a support at 25.08 and a resistance at 26.21.
The 30-day price range runs from 23.47 to 26.80, illustrating modest volatility in the near term.
Forecasts show a rising multi-year path: 2026 min 25.08, avg 25.08, max 32.60 (ROI 0); 2027 avg 29.63; 2028 avg 35.66; 2029 avg 39.29; 2030 avg 40.93; 2031 avg 44.31; 2032 avg 46.11; 2033 avg 48.70; 2034 avg 55.38; 2035 avg 63.85; 2040 avg 80.37; 2050 avg 167.21. The ROIs accompany these levels, rising from 0 to 566.7 by 2050, with sentiment turning bullish from 2028 onward.
A major floor 8.4% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.1% away) — a key level to hold.
The nearest ceiling, 8.4% above — a clean break opens room to run.
A major ceiling 18.1% above — clearing it would confirm fresh momentum.
Key PFE support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PFE market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $24.05 | Buy | $24.14 | Buy |
| MA 10 | $24.12 | Buy | $24.23 | Sell |
| MA 20 | $24.71 | Sell | $24.57 | Sell |
| MA 50 | $25.44 | Sell | $25.30 | Sell |
| MA 100 | $26.31 | Sell | $25.73 | Sell |
| MA 200 | $25.87 | Sell | $25.81 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.45 | Neutral |
| Stoch RSI (14) | 94.98 | Sell |
| CCI (20) | -47.35 | Neutral |
| Williams %R (14) | -64.54 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -2.22 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 35.46 | Neutral |
| TRIX (15) | -0.27 | Sell |
| Awesome (5,34) | -1.11 | Sell |
| Ultimate (7,14,28) | 46.26 | Neutral |
| Momentum (10) | 0.50 | Buy |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 24.15 | Buy |
| ADX (14) | 21.18 | Sell |
| ATR (14) | 0.28 | Info |
Near-term technical picture:
- Sentiment: NEUTRAL
- RSI14: 40
- SMA50: 26.20
- SMA200: 25.88
- Support: 25.08
- Resistance: 26.21
30-day range: 23.47 to 26.80.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $23.67 | $24.17 | $30.48 | 0% | Neutral | |
| $23.08 | $28.18 | $35.97 | +17% | Neutral | |
| $27.18 | $33.81 | $44.33 | +40% | Bullish | |
| $29.01 | $36.64 | $49.06 | +52% | Bullish | |
| $30.42 | $38.95 | $53.09 | +61% | Bullish | |
| $32.01 | $41.48 | $57.44 | +72% | Bullish | |
| $32.49 | $42.57 | $59.79 | +76% | Bullish | |
| $34.84 | $46.14 | $65.64 | +91% | Bullish | |
| $38.03 | $50.87 | $73.22 | +110% | Bullish | |
| $43.04 | $58.10 | $84.57 | +140% | Bullish | |
| $52.29 | $73.63 | $112.31 | +205% | Bullish | |
| $99.72 | $150.61 | $246.25 | +523% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $23.67 | $24.17 | $28.33 | +0.00% |
| August 2026 | $20.47 | $23.96 | $28.66 | -0.85% |
| September 2026 | $20.89 | $24.57 | $29.61 | +2.51% |
| October 2026 | $20.87 | $24.65 | $29.90 | +0.33% |
| November 2026 | $20.53 | $24.33 | $29.68 | -1.28% |
| December 2026 | $20.91 | $24.86 | $30.48 | +2.18% |
Click any year to see its month-by-month PFE forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect PFE to range from $23.67 to $30.48 through 2026. The $24.17 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The PFE price prediction for 2027 points to an average of $28.18 (low $23.08, high $35.97) — a potential gain of +17% on today's $24.17. A consolidation phase looks the most probable path here.
In 2028, PFE is projected to trade between $27.18 and $44.33, averaging $33.81 — a potential gain of +40% from today's $24.17. That is up +20% on the projected 2027 average. Momentum favours further upside here.
Pfizer Inc.'s 2029 outlook centres on $36.64, within a $29.01 to $49.06 range. That is up +8% on the projected 2028 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, PFE could reach as high as $53.09, with a base case around $38.95 and support toward $30.42 — roughly +61% from $24.17. Momentum favours further upside here.
Expect PFE to range from $32.01 to $57.44 through 2031. The $41.48 average target implies a +72% move from current prices. That is up +7% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The PFE price prediction for 2032 points to an average of $42.57 (low $32.49, high $59.79) — a potential gain of +76% on today's $24.17. Momentum favours further upside here.
In 2033, PFE is projected to trade between $34.84 and $65.64, averaging $46.14 — a potential gain of +91% from today's $24.17. That is up +8% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Pfizer Inc.'s 2034 outlook centres on $50.87, within a $38.03 to $73.22 range. That is up +10% on the projected 2033 average. That marks a +110% change versus current levels. Momentum favours further upside here.
By 2035, PFE could reach as high as $84.57, with a base case around $58.10 and support toward $43.04 — roughly +140% from $24.17. Buyers look set to stay in control over this stretch.
Expect PFE to range from $52.29 to $112.31 through 2040. The $73.63 average target implies a +205% move from current prices. That is up +27% on the projected 2035 average. Momentum favours further upside here.
The PFE price prediction for 2050 points to an average of $150.61 (low $99.72, high $246.25) — a potential gain of +523% on today's $24.17. Buyers look set to stay in control over this stretch.
Investing $1,000 in PFE today (≈ 41.373604 PFE) could be worth
$6,231.11
+$5,231.11 (+523%) by 2050 · US Dollar
Based on the average projected PFE price of $150.61 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PFEwould be worth at today's price.
$1,000 invested in PFE on Jul 10, 2025 (≈ 38.789758 PFE) would be worth
$937.55
-$62.45 (-6.2%) today · 0.94× · US Dollar
Based on a PFE entry price of $25.78 vs. today's $24.17.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $24.32 | $993.83 | -0.6% |
| 1 month ago | $25.6 | $944.14 | -5.6% |
| 3 months ago | $26.92 | $897.85 | -10.2% |
| 6 months ago | $25.27 | $956.47 | -4.4% |
| 1 year ago | $25.78 | $937.55 | -6.2% |
| All time (5.0y) ago | $39.65 | $609.58 | -39.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PFE forecast.
Our base-case forecast reaches $48.00 around 2034.
Implied market cap at $48.00: $273.57B
Multi-year forecast interpretation:
- 2026: avg 25.08, min 25.08, max 32.60, ROI 0, sentiment NEUTRAL. - 2027: avg 29.63, max 37.89, ROI 18.2, sentiment NEUTRAL. - 2028: avg 35.66, max 46.81, ROI 42.2, sentiment BULLISH.
- 2029: avg 39.29, max 52.66, ROI 56.7, sentiment BULLISH. - 2030: avg 40.93, max 55.84, ROI 63.2, sentiment BULLISH. - 2031: avg 44.31, max 61.40, ROI 76.7, sentiment BULLISH. - 2032: avg 46.11, max 64.80, ROI 83.8, sentiment BULLISH.
- 2033: avg 48.70, max 69.32, ROI 94.2, sentiment BULLISH. - 2034: avg 55.38, max 79.77, ROI 120.8, sentiment BULLISH. - 2035: avg 63.85, max 92.99, ROI 154.6, sentiment BULLISH. - 2040: avg 80.37, max 122.65, ROI 220.5, sentiment BULLISH.
- 2050: avg 167.21, max 273.49, ROI 566.7, sentiment BULLISH.
Overall, the trajectory suggests a sustained uptrend with bullish sentiment expanding into the late 2020s and beyond. While the figures are estimates and not guarantees, the longer-horizon path envisions meaningful upside relative to the current price, tempered by the inherent uncertainty of equity markets.
Tap a question to reveal the answer.
The forecast shows min 31.95, avg 40.93, max 55.84 with ROI 63.2 and sentiment BULLISH.
Long-term projections show bullish sentiment from 2028 onward, with averages rising to 80.37 by 2040 and 167.21 by 2050; ROIs reach 220.5 and 566.7 respectively, though these are estimates and not guarantees.
Yes. The forecast max values include 122.65 in 2040 and 273.49 in 2050, indicating the possibility of crossing $100.
Current price is 25.08 and market cap is 142.94B.
RSI14 is 40, SMA50 is 26.20, SMA200 is 25.88, with support at 25.08 and resistance at 26.21; 30-day range is 23.47 to 26.80.
Pfizer Inc. Community Discussion
0Share your Pfizer Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.